INDIVIDUAL RESULTS VARY: Responses to Wegovy may differ based on factors such as adherence to treatment, lifestyle, metabolism, and underlying health conditions
Appetite suppression is common, as shown in a clinical study of semaglutide, where 75% of patients reported decreased appetite, and over time, those behavioral changes translate into measurable laboratory differences
The FTCs April 2024 warning letters specifically referenced device patents on auto-injectors for weight-loss and diabetes treatments, signaling regulatory awareness of this risk
This increases oxidative stress, and leaves the body vulnerable to further damage from toxins
(In Russ.) doi: 10.17816/RCF193281-290 Boldyrev AA, Kulebyakin KY, Arzumanyan ES, Berezov TT